

Supplementary Table S1. Comparison of overall characteristics of with and without DM of D2T vs. non-D2T PsA.

Variables	D2T PsA patients n=33			Non-D2T PsA patients n=138		
	with DM	without DM	p	with DM	without DM	p
Sex, (female), n (%)	8 (57.1)	14 (7.7)	0.459	4 (25)	40 (32.8)	0.530
Age, year, mean $\pm$ SD	61.2 $\pm$ 8.5	46.5 $\pm$ 10.3	<0.001	57 $\pm$ 12.6	47.3 $\pm$ 12.1	0.003
Age disease onset, years, mean $\pm$ SD	48.7 $\pm$ 12.7	40 $\pm$ 11.38	0.048	51.2 $\pm$ 12.3	42.5 $\pm$ 12.6	0.011
Current smoking, n (%)	5 (35.7)	10 (52.6)	0.335	2 (12.5)	44 (36.1)	0.060
Alcohol consumption, drinkers, n (%)	6 (42.9)	3 (15.8)	0.122	1 (6.3)	23 (18.9)	0.305
BMI (kg/m ²), mean $\pm$ SD	27.6 $\pm$ 5.1	28.2 $\pm$ 5.5	0.754	30.7 $\pm$ 5.7	26.9 $\pm$ 5.3	0.009
PsA disease duration, year, median (IQR)	12.5 (36)	4 (21)	0.050	3 (15)	3 (20)	0.896
Psoriasis duration, year, median (IQR)	13 (20)	13 (20)	0.024	16.5 (40)	9 (55)	0.349
Peripheral involvement $\pm$ except pure axial, n (%)	13 (92.9)	19 (100)	0.424	15 (93.8)	97 (79.5)	0.306
Axial involvement $\pm$ other types, n (%)	3 (21.4)	9 (47.4)	0.126	4 (25)	45 (36.9)	0.350
Enthesitis, ever, n (%)	9 (64.3)	4 (21.1)	0.012	8 (50)	57 (46.7)	0.805
Dactylitis, ever, n (%)	0	5 (26.3)	0.057	2 (12.5)	45 (36.9)	0.089
Nail involvement, ever, n (%)	5 (26.3)	9 (64.3)	0.040	4 (25)	47 (38.5)	0.292
RF positivity, n (%)	1 (7.1)	0	0.424	0	1 (0.8)	1
Anti-CCP positivity, n (%)	1 (7.7)	0	1	0	5 (4.6)	1
ANA positivity, n (%)	1 (7.1)	2 (14.3)	1	1 (6.7)	12 (11)	1
HLA-B27 positivity, n (%)	2 (33.3)	4 (40)	1	0	8 (13.1)	0.587
TJC (0-68), median (IQR)	6 (24)	6 (319)	0.957	1 (14)	1 (18)	0.746
SJC (0-66), median (IQR)	5 (10)	1 (109)	0.186	0 (14)	0 (8)	0.297
PhGA (0-100), median (IQR)	60 (70)	40 (90)	0.012	20 (50)	10 (80)	0.652
PGA (0-100), median (IQR)	80 (70)	50 (100)	0.032	30 (80)	30 (100)	0.746
Pain VAS (0-100), median (IQR)	80 (70)	50 (90)	0.060	35 (100)	20 (100)	0.790
Morning stiffness, min, median (IQR)	90 (120)	60 (120)	0.056	0 (60)	10 (180)	0.106
ESR, mm/h, median (IQR)	39 (59)	33 (62)	0.271	32 (49)	19 (87)	0.001
CRP, mg/dl, median (IQR)	8.54 (14.5)	9.48 (34.1)	0.627	5.2 (23.6)	2.9 (61.3)	0.184
DAPSA, mean $\pm$ SD	34.7 (12.6)	32.6 (11.7)	0.577	18.2 (13)	13.3 $\pm$ 11.3 0.425	
BSA, median (IQR)	0 (2)	0 (5)	1	1 (4)	0 (15)	0.232
CCI, median (IQR)	1 (3)	0 (0)	0.001	1 (2)	0 (3)	0.001
Hypertension, n (%)	10 (71.4)	4 (21.1)	0.004	11 (68.8)	31 (25.4)	0.001
Diabetes mellitus, n (%)	3 (21.1)	1 (5.3)	0.288	3 (18.8)	4 (3.3)	0.034
Thyroid disease, n (%)	2 (14.3)	0	0.172	2 (12.5)	18 (14.8)	1
Methotrexate, n (%)	2 (14.3)	5 (26.3)	0.670	1 (6.3)	12 (9.8)	1
Leflunomide, n (%)	9 (64.3)	13 (68.4)	1	13 (81.3)	70 (57.9)	0.072
Sulfasalazine, n (%)	5 (35.7)	7 (36.8)	1	3 (18.8)	40 (38.8)	0.390
GCS, n (%)	2 (14.3)	1 (5.3)	0.561	3 (18.8)	12 (9.8)	0.383
TNFi, n (%)	9 (64.3)	5 (45.5)	0.435	3 (23.1)	31 (26.5)	0.533
Secukinumab, n (%)	6 (42.9)	6 (31.6)	0.506	6 (37.5)	35 (28.7)	0.562
Ustekinumab, n (%)	6 (42.9)	9 (47.7)	0.797	0	10 (8.2)	0.605
Ixekizumab, n (%)	0	1 (5.3)	1	0	1 (0.8)	1
≥ 2 biological use, n (%)	2 (14.3)	1 (5.3)	0.561	1 (6.3)	5 (4.1)	0.530
≥ 3 biological use, n (%)	14 (100)	19 (100)	1	5 (31.3)	22 (27.1)	0.528

ANA: antinuclear antibody; Anti-CCP: anti-cyclic citrullinated peptide; BSA: body surface area; BMI: Body Mass Index; CCI: Charlson Comorbidity Index; GCS: glucocorticoids; CRP: C-reactive protein; DAPSA: Disease Activity Score for Psoriatic Arthritis; ESR: erythrocyte sedimentation rate; TJC: tender joint count; PGA: patient global assessment, PhGA: physician global assessment; PsA: psoriatic arthritis; RF: rheumatoid factor; NA: not applicable; TNFi: TNF alpha inhibitors; SD: standard deviation. n: number of patients.

Bold values are significant at $p < 0.05$.

Supplementary Table S2. Comparison of overall characteristics of with and without FMS of D2T vs .non D2T PsA.

Variables	D2T PsA patients n=33			Non-D2T PsA patients n=138		
	with FMS	without FMS	p	with FMS	without FMS	p
Sex, (female), n (%)	8 (57.1)	14 (7.7)	0.459	11 (91.7)	83 (65.9)	0.103
Age, year, mean±SD	50.1 ± 11.1	53.9 ± 12.4	0.407	50.8±8.7	48.2±12.7	0.488
Age disease onset, years, mean ± SD	47.1 ± 12.2	42.2 ± 12.6	0.316	46±8.7	43.5±13.1	0.483
Current smoking, n (%)	11 (47.8)	4 (40)	0.722	2 (16.7)	44 (34.9)	0.337
Alcohol consumption, drinkers n (%)	8 (34.8)	1 (10)	0.217	2 (16.7)	22 (17.5)	1
BMI (kg/m ²), mean ± SD	28.4 ± 5	27.7 ± 5.7	0.752	24.9 ± 5.5	27.6 ± 13.4	0.018
PsA disease duration, year, median (IQR)	3 (6)	12 (35)	0.001	3 (16)	3 (20)	0.976
Psoriasis duration, year, median (IQR)	13 (20)	13 (20)	0.954	12 (33)	9 (55)	0.987
Peripheral involvement ± except pure axial, n (%)	21 (91.3)	9 (90)	1	10 (83.3)	102 (81)	1
Axial involvement ± other types, n (%)	3 (21.4)	9 (39.1)	0.710	12 (36.4)	46 (36.5)	0.538
Enthesitis, ever, n (%)	4 (40)	9 (39.1)	1	7 (58.3)	58 (46)	0.415
Dactylitis, ever, n (%)	2 (20)	5 (22.7)	1	5 (41.7)	42 (33.3)	0.542
Nail involvement, ever, n (%)	5 (50)	9 (39.1)	0.707	9 (75)	42 (33.3)	0.009
RF positivity, n (%)	1 (10)	0	0.303	0	1 (0.8)	1
Anti-CCP positivity, n (%)	0	1 (5.6)	1	1 (9.1)	4 (3.5)	0.377
ANA positivity, n (%)	0	3 (14.3)	0.551	2 (18.2)	11 (9.7)	0.324
HLA-B27 positivity, n (%)	2 (25)	4 (50)	0.608	2 (28.6)	6 (9.8)	0.188
TJC (0-68), median (IQR)	11.5 (28)	5 (12)	0.006	0 (6)	1 (18)	0.396
SJC (0-66), median (IQR)	1 (10)	3 (10)	0.743	0 (1)	0 (14)	0.168
PhGA (0-100), median (IQR)	50 (45)	50 (90)	1	10 (30)	10 (80)	0.551
PGA (0-100), median (IQR)	65 (70)	60 (90)	0.180	30 (50)	30 (100)	0.505
Pain VAS (0-100), median (IQR)	80 (60)	50 (90)	0.167	40 (80)	20 (100)	0.254
Morning stiffness, min, median (IQR)	65 (105)	60 (120)	0.889	10 (60)	10 (180)	0.861
ESR, mm/h, median (IQR)	33 (49)	39 (63)	0.569	22.5 (19)	20 (87)	0.703
CRP, mg/dl, median (IQR)	6.95 (16.4)	11.2 (31.1)	0.075	1.95 (6.6)	3.23 (61.3)	0.131
DAPSA, mean ± SD	37.8 (12.1)	32 (11.8)	0.792	11 (6.1)	14.2 (11.9)	0.763
BSA, median (IQR)	0.5 (2)	0 (5)	0.083	0 (4)	1 (15)	0.773
CCI, median (IQR)	0 (2)	0 (3)	0.406	0 (2)	0 (3)	0.907
Hypertension, n (%)	6 (60)	13 (56.5)	1	5 (41.7)	37 (29.4)	0.512
Diabetes mellitus, n (%)	3 (30)	11 (47.8)	0.455	0	16 (12.7)	0.360
Thyroid disease, n (%)	1 (10)	3 (13)	1	3 (25)	17 (13.5)	0.382
Methotrexate, n (%)	7 (70)	15 (65.2)	1	7 (58.3)	76 (60.8)	1
Leflunomide, n (%)	3 (30)	9 (39.1)	0.710	2 (16.7)	41 (32.5)	0.341
Sulfasalazine, n (%)	1 (10)	2 (8.7)	1	1 (8.3)	14 (11.1)	1
GCs, n (%)	3 (50)	11 (57.9)	1	1 (11.1)	33 (37.1)	0.156
TNFi, n (%)	3 (30)	9 (39.1)	0.710	3 (25)	38 (30.2)	1
Secukinumab, n (%)	6 (60)	9 (39.1)	0.448	1 (8.3)	9 (7.1)	1
Ustekinumab, n (%)	0	1 (4.5)	1	0	1 (0.8)	1
Ixekizumab, n (%)	1 (10)	2 (8.7)	1	0	6 (4.8)	1
≥2 biological use, n (%)	10 (100)	23 (100)	NA	2 (16.7)	30 (23.8)	0.732
≥3 biological use, n (%)	6 (60)	13 (56.5)	1	1 (8.3)	15 (11.9)	1

ANA: antinuclear antibody; Anti-CCP: anti-cyclic citrullinated peptide; BSA: body surface area; BMI: Body Mass Index; CCI: Charlson Comorbidity Index; GCs: glucocorticoids; CRP: C-reactive protein; DAPSA: Disease Activity Score for Psoriatic Arthritis; ESR: erythrocyte sedimentation rate; TJC: tender joint count; PGA: patient global assessment; PhGA: physician global assessment; PsA: psoriatic arthritis; RF: rheumatoid factor; NA: not applicable; TNFi: TNF alpha inhibitors; SD: standard deviation. n: number of patients.

Bold values are significant at $p < 0.05$.